Stay updated on Dociparstat for Severe COVID-19 High-Risk Adults Clinical Trial
Sign up to get notified when there's something new on the Dociparstat for Severe COVID-19 High-Risk Adults Clinical Trial page.

Latest updates to the Dociparstat for Severe COVID-19 High-Risk Adults Clinical Trial page
- Check5 days agoChange DetectedMinor metadata update: Revision v3.3.2 added and v3.3.1 removed, with no changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check13 days agoChange DetectedThe Publications section text was updated to clarify that publications are automatically filled in from PubMed and may not be about the study, and the revision label changed from v3.2.0 to v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedThe government funding operating-status notice has been removed from the page.SummaryDifference0.3%

- Check34 days agoChange DetectedNo substantive changes detected between the two screenshots. Core study information remains unchanged, with only cosmetic formatting or layout differences observed.SummaryDifference0.4%

- Check63 days agoChange DetectedUpdated operating-status notice and added Jazz Pharmaceuticals with v3.2.0; removed Chimerix and v3.1.0.SummaryDifference4%

- Check70 days agoChange DetectedCore content shifted toward inorganic chemical categories with a version update (v3.1.0), while drug-safety topics and the older version tag v3.0.2 were removed.SummaryDifference1%

Stay in the know with updates to Dociparstat for Severe COVID-19 High-Risk Adults Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dociparstat for Severe COVID-19 High-Risk Adults Clinical Trial page.